Cargando…

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients

This study aims to analyze in depth the role of IFNα in the upregulation of BLyS in different leukocyte populations and the possible relationship of these molecules with IL-17 and other pathogenic cytokines in SLE. Thus, IFNAR1 and membrane BLyS (mBLyS) expression was upregulated on various blood ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	López, Patricia, Rodríguez-Carrio, Javier, Caminal-Montero, Luis, Mozo, Lourdes, Suárez, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742957/ https://www.ncbi.nlm.nih.gov/pubmed/26847824 http://dx.doi.org/10.1038/srep20651

Ejemplares similares

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)
por: Stohl, William
Publicado: (2010)

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
por: Collins, Christopher E, et al.
Publicado: (2006)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
por: Stohl, William
Publicado: (2003)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

The current status of targeting BAFF/BLyS for autoimmune diseases
por: Ramanujam, Meera, et al.
Publicado: (2004)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019)

G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
por: Scapini, Patrizia, et al.
Publicado: (2003)

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin
por: Parameswaran, Reshmi, et al.
Publicado: (2012)

Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells
por: Zhu, Jing, et al.
Publicado: (2012)

Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Human BLyS Facilitates Engraftment of Human PBL Derived B Cells in Immunodeficient Mice
por: Schmidt, Madelyn R., et al.
Publicado: (2008)

Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B
Publicado: (2012)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
por: Furie, Richard, et al.
Publicado: (2008)

Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus
por: Suárez-Díaz, Silvia, et al.
Publicado: (2023)

Roles for BLyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells
por: Sindhava, Vishal J., et al.
Publicado: (2013)

B Lymphocyte Stimulator (BLyS) Is Expressed in Human Adipocytes In Vivo and Is Related to Obesity but Not to Insulin Resistance
por: Müller, Nike, et al.
Publicado: (2014)

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis
por: Wilkinson, Christel, et al.
Publicado: (2020)

Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo
por: Luster, Troy A., et al.
Publicado: (2012)

Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2014)

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation
por: Goenka, Radhika, et al.
Publicado: (2014)

BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
por: Cai, Shaozhe, et al.
Publicado: (2023)

APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2022)

Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS)
por: Gor, Dennis O, et al.
Publicado: (2011)

High Expression Levels of BLyS/BAFF by Blood Dendritic Cells and Granulocytes Are Associated with B-cell dysregulation in SIV-Infected Rhesus Macaques
por: Poudrier, Johanne, et al.
Publicado: (2015)

IL-17 in Systemic Lupus Erythematosus
por: Crispín, José C., et al.
Publicado: (2010)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2019)

Effects of 1,25-dihydroxyvitamin D(3) on IL-17/IL-23 axis, IFN-γ and IL-4 expression in systemic lupus erythematosus induced mice model
por: Faraji, Fatemeh, et al.
Publicado: (2016)

Common and Specific Associations of Anti-SSA/Ro60 and Anti-Ro52/TRIM21 Antibodies in Systemic Lupus Erythematosus
por: Menéndez, Aurora, et al.
Publicado: (2013)

Relationship Between T-Cell Exosomes and Cellular Subsets in SLE According to Type I IFN-Signaling
por: López, Patricia, et al.
Publicado: (2020)

Blood B Lymphocyte Stimulator (BLyS)/BAFF levels may reflect natural immunity to HIV in highly exposed uninfected Beninese Commercial Sex Workers
por: Sabourin-Poirier, Catherine, et al.
Publicado: (2016)

Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores
por: van den Hoogen, Lucas L, et al.
Publicado: (2018)

IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from human marginal zone B cells as well as from circulating peripheral blood B cells from autoimmune patients
por: Ettinger, Rachel, et al.
Publicado: (2007)

Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c(+) B-cells in the genital tract
por: Fourcade, Lyvia, et al.
Publicado: (2019)

Impact of IL-34, IFN-α and IFN-λ1 on activity of systemic lupus erythematosus in Egyptian patients
por: Adel, Yasmin, et al.
Publicado: (2020)

Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients
por: López, Patricia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_va9ohpcq526bqrldp4ph88lr8i